The Efficacy of Lambrolizumab in Advanced Melanoma
Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.
Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.
Clinical Pearls
Researchers have seen clinically meaningful activity in a substantial number of patients, Ribas says. In the trial, the overall response rate was 38% and 90% of patients experienced durable response. Ribas notes that adverse events in the trial were minimal.
- Clinically meaningful activity was observed in the trial
- The overall response rate was 38%, pooled across all doses and schedules and including both ipilimumab-naive and ipilimumab-pretreated patients
- Preliminary data suggest that lambrolizumab has significant antitumor activity and is well tolerated with manageable side effects in both ipilimumab-naive and ipilimumab-pretreated patients with melanoma
<<<
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
